天眼查信息显示，苏州君跻基因科技有限公司的股东为：孙健、苏州君跻智未管理咨询合伙企业（有限 合伙）、武汉市明君合纵创业投资基金合伙企业（有限合伙）、杭州君富股权投资合伙企业（有限合 伙）、苏州吴中生物医药产业园投资有限公司。 12月15日，天眼查融资历程显示，苏州君跻基因科技有限公司近日获得"A轮"融资，涉及融资金额近亿 人民币，投资机构为天汇资本，金桥基金，金海创投，光谷产业投资。 资料显示，苏州君跻基因科技有限公司法定代表人为孙健，成立于2022年，位于苏州市，是一家以从事 专业技术服务业为主的企业。企业注册资本707.4162万人民币，并已于2025年完成了A轮，交易金额近 亿人民币。 通过天眼查大数据分析，苏州君跻基因科技有限公司共对外投资了5家企业，知识产权方面有商标信息8 条，专利信息29条，此外企业还拥有行政许可6个。 来源：市场资讯 ...

Core Insights - BGI is one of the largest genomics companies globally, operating DNA sequencing laboratories and processing genetic data for various sectors [2][3] - Concerns are rising regarding BGI's potential to surpass Huawei in scale and implications, particularly in the realm of genetic data collection [3][8] - U.S. officials express fears about the implications of BGI's operations, including the potential for military applications and genetic enhancement [5][7] Company Overview - BGI originated as the Beijing Genomics Institute, closely linked to China's national genome projects, and has evolved into a global commercial entity [1] - The company provides services such as DNA sequencing, prenatal testing, cancer screening, and large-scale population genetic analysis [1] Market Position - BGI has established a significant global presence, processing genetic data for hospitals, pharmaceutical companies, and researchers across numerous countries [2] - The company is perceived as a strategic asset in the biotechnology sector, with its genetic data collection capabilities raising concerns about a "DNA arms race" [7] Political and Security Concerns - U.S. lawmakers have warned about BGI's close ties to the Chinese Communist Party and military, suggesting that commercial data is often intertwined with state security needs [6] - Senator Mark Warner emphasizes the need for vigilance regarding BGI's data collection practices, which could have far-reaching implications for national security [7][12] Legislative Actions - The U.S. Congress is considering the BIOSECURE Act to limit the operations of Chinese biotech firms like BGI within the U.S. [13] - BGI has publicly stated that it complies with regulations and does not access Americans' personal data [13] Technological Competition - Warner draws parallels between BGI's rapid growth and Huawei's rise, highlighting the need for the U.S. to adapt its intelligence and regulatory approaches to address emerging biotech threats [12][14] - The U.S. intelligence community is criticized for its slow response to the biotech challenge, with calls for a more advanced approach to monitoring technological advancements [14][15]

祁乐提出三方面建议，希望可以系统性赋能龙江生物经济发展。一是服务"健康龙江"，持续落地普惠项目。"健康 中国"是国家重大战略，保障人民健康是发展的根本目的，华大集团将全力支持"健康龙江"建设。此前，集团已实 施多项惠民工程，切实降低了医保支出，保障居民健康，是预防医学与临床治疗结合的模式探索。二是立足寒地 特点，发展精准医学产业。黑龙江省独特的地理气候和人群特征，是科研与产业融合的独特资源。华大集团规划 启动"龙江百万健康队列"计划，系统收集寒地人群的多组学健康数据，建立"寒地人群多组学数据库"，吸引科研 机构和药企合作，围绕心脑血管等寒地高发疾病，开发新的筛查、诊断技术和药物。并将以此为基础，建设"寒地 特色疾病研究与预防中心"，将区域健康问题，转化为集数据服务、新药研发、健康管理于一体的新产业。三是保 障"黑土粮仓"安全，发展现代种业技术。华大集团提出实施"黑土粮仓'芯'工程"，这里的"芯"就是种业核心技术。 发挥华大基因测序和基因编辑能力，与省内科研机构合作，加速开发具有自主知识产权的作物品种，如高蛋白大 豆、高品质水稻等，保障种源自主可控。预计启动"黑土地微生物组"研究计划，在此基础上，开发并应用能够 ...

Core Insights - Beijing Nuohe Yuanqi Gene Technology Co., Ltd. has been established with a registered capital of 30 million yuan [1] - The company is wholly owned by Nuohe Zhiyuan [1] - The business scope includes natural science research and experimental development, medical research and experimental development, biotechnology product technology research and development, and electronic product sales [1] Company Overview - The legal representative of the newly established company is Yu Yang [1] - The company focuses on various research and development activities in the fields of natural sciences and biotechnology [1]

Core Insights - The completion of the Human Genome Project in 2003 has provided a foundational understanding of life, yet challenges remain in interpreting this vast amount of genetic data. The launch of the Genos model by BGI Life Sciences and Zhijiang Laboratory aims to address these challenges by offering a deployable genomic universal foundational model with 100 billion parameters [1]. Group 1: Genos Model Advantages - Genos enhances both interpretative and deployment capabilities compared to existing models, primarily due to the expansion of training data. It integrates multiple authoritative public resources, including the Human Pan-Genome Reference Consortium (HPRC) and the Human Genome Structural Variation Consortium (HGSVC), utilizing 636 high-quality human genomes to better reflect human genetic diversity [2]. - The model's deployment capability is improved through a "mixed expert" architecture, which efficiently coordinates relevant algorithms to reduce inference costs and resource consumption, addressing the common issue of large models being difficult to deploy. Genos is also open-source, available in both 1.2 billion and 100 billion parameter versions on platforms like HuggingFace and Modao [2]. Group 2: Clinical and Research Implications - Clinical testing has demonstrated Genos's effectiveness, achieving a 92% accuracy rate in interpreting pathogenic mutations, which increases to 98.3% when combined with scientific foundational models. This performance surpasses existing top-level models [2]. - In research, AI models like Genos can transform the process of identifying pathogenic loci from a "needle in a haystack" approach to "precise navigation," significantly reducing the time required for rare disease and complex mechanism studies [3]. Group 3: Future Prospects and Challenges - The advancement of AI models in genomics is expected to shift drug development from a "trial-and-error" approach to "design-based" innovation, thereby reducing experimental iterations and costs [4]. - Future development faces three main challenges: expanding training databases to include more disease samples, establishing comprehensive ethical and safety standards, and enhancing interdisciplinary collaboration to integrate AI with clinical data systems and biological experimental platforms [4]. - The successful implementation of AI in genomics is anticipated to accelerate the arrival of precision medicine, with the Genos model being a significant step towards unlocking the potential of the life economy [4].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本公告的內容概不負責， 對其準確性或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Annoroad Gene Technology (Beijing) Co., Ltd. 安 諾 優 達 基 因 科 技（ 北 京 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 警告 本公告乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會 （「證監會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 閣下閱覽本公告， 即代表 閣下知悉、接納並向安諾優達基因科技（北京）股份有限公司（「本公司」）、 其聯席保薦人、整體協調人、顧問或銀團成員表示同意： – 1 – (a) 在聯交所網站登載本公告，並不引起本公司、其聯席保薦人、整體協調人、顧 問或銀團成員在香港或任何其他司法權區必須進行發售或配售活動的責任。本 公司最終會否進行發售或配售仍屬未知之數； (b) 本公告所涉及的上市申請並未獲批准，聯交所及證監會或會接納、發回或拒絕 有關的公開發售及╱或上市申請； (c) 本 ...

Core Viewpoint - The article highlights the rapid development of the biomedical industry in Hangzhou, particularly in the Hangzhou Medical Port Town, which has become a hub for over 1,800 biotech companies, including major global pharmaceutical firms and numerous innovative enterprises [3][8]. Group 1: Industry Development - The Hangzhou Medical Port Town covers an area of 4.92 square kilometers and hosts more than 1,800 biomedical enterprises, including leading global pharmaceutical companies such as Pfizer, Merck, and Bayer [3]. - The Zhejiang Free Trade Zone has been instrumental in promoting the biomedical industry, focusing on open innovation across the entire industry chain, aiming to establish Hangzhou as an international center for biomedical technology and innovation [3][6]. - The establishment of a joint regulatory mechanism for high-risk imported special items has significantly improved customs efficiency, reducing approval times from 20 working days to just 2 days, thus enhancing competitiveness in global drug development [5][8]. Group 2: Company Insights - Lianchuan Biotechnology, a key player in the gene technology sector, has been operating in Hangzhou for nearly 20 years and has developed a strong focus on high-throughput gene sequencing and bioinformatics services [4][6]. - The company has faced challenges with importing critical standards for its OLINK proteomics testing, which required Swedish plasma as a control standard, but has successfully navigated these challenges through the new regulatory framework [4][5]. - Lianchuan has expanded its operations significantly, establishing a nationwide research service network and entering the IPO stage on the Beijing Stock Exchange, serving over 90% of key universities in China [6][8]. Group 3: Innovation and Ecosystem - The integration of 14 universities and 250,000 students in the Qiantang District has created a robust talent pool, supporting the development of the biomedical industry [7]. - The establishment of high-level platforms such as the Zhejiang University Intelligent Innovative Drug Research Institute and the Pfizer Smart Medical Innovation Center has contributed to forming a complete industrial chain from research to commercialization [7]. - The Qiantang District has developed a comprehensive innovation ecosystem that covers basic research, technological breakthroughs, and industrialization, positioning itself as a critical player in the global biomedical landscape [7][8].

Core Insights - BGI Genomics celebrated its 26th anniversary with a global product launch, emphasizing the theme "Health and Beauty for All" and marking a new phase in China's genetic technology industry [1] - The company introduced several key products and solutions, including the SEQALL comprehensive genomic solution and the BGI Smart Medical System, aimed at enhancing public health and personalized health management [1][2] - BGI's Vice President proposed a "Public Health Big Data Era," advocating for a data-driven and intelligent collaborative health system to address traditional public health challenges [1][2] Product and Service Innovations - The 133111i multi-omics health management model was launched, focusing on personalized health strategies rather than traditional one-size-fits-all approaches [1][2] - The GigaLab Smart Laboratory, described as a "data black factory," automates the entire process from sample handling to result output, ensuring consistent data quality and enabling large-scale implementation [2] - The i99 Smart Health platform integrates health insights and personalized plan customization, promoting a shift from "passive healthcare" to "active health management" [2] Strategic Developments - BGI has initiated the construction of the "BGI Space Smart Health Center," collaborating with various organizations to establish a strategic presence in key regions of China, including Shenzhen, Wuhan, and Tianjin [3] - The company's evolution from a research institution to a comprehensive technology group reflects the broader development of China's genetic technology sector since its involvement in the Human Genome Project in 1999 [3][4]

Core Insights - Shenzhen has cultivated a large number of high-quality listed companies over the past 45 years, which are seen as the "power source" and "ballast" of the national economy [1] - The story of YingShi Innovation, which became the global leader in panoramic cameras, exemplifies the rapid growth and innovation characteristic of Shenzhen companies [2] - Shenzhen's listed companies have shown resilience and vitality, with a significant increase in the number of A-share listed companies [2] Group 1: Company Growth and Market Position - YingShi Innovation achieved a global market share of over 50% in the panoramic camera sector, with more than 70% of its revenue coming from overseas markets [2] - Bawei Storage has seen its revenue and net profit grow approximately threefold and fivefold, respectively, from 2020 to 2024 [3] - Shenzhen's listed companies are projected to have a combined overseas business revenue of 11.4 trillion yuan in 2024, reflecting a year-on-year growth of 15.9% [3] Group 2: Industry Leadership and Innovation - Shenzhen is recognized as the "first city of new energy vehicles" in China, with BYD achieving a milestone of producing its 13 millionth vehicle [5] - The city is also leading in the low-altitude economy, with over 2,300 companies in this sector and significant advancements in eVTOL technology [6] - In the field of embodied intelligence, Shenzhen has the largest number of robot companies in the country, with 74,032 enterprises in the robotics industry [6] Group 3: Financial Sector and Capital Support - The financial sector in Shenzhen is growing, with a projected value added of 471.05 billion yuan in 2024, accounting for approximately 12.8% of GDP [7] - Shenzhen's capital market has supported 11 companies in going public in 2024, raising 9.392 billion yuan, leading the nation in both the number of IPOs and fundraising [8] - The concept of "patient capital" has been emphasized in Shenzhen's government reports, highlighting the importance of long-term investment in supporting emerging industries [9] Group 4: Economic Performance - Shenzhen's GDP is projected to reach 3.68 trillion yuan in 2024, with a year-on-year growth of 5.8% [10] - The city achieved a GDP of 1.83 trillion yuan in the first half of 2025, reflecting a growth of 5.1% [10]

Group 1 - The core viewpoint highlights the resilience and innovation of Shenzhen's listed companies, showcasing their ability to thrive under pressure and contribute significantly to the economy [1][2][8] - Shenzhen has nurtured a large number of high-quality listed companies over the past 45 years, which have become key drivers of the national economy [1][2] - The number of A-share listed companies in Shenzhen reached 425 by June 2023, an increase of 128 compared to the same period in 2020 [2] Group 2 - The global market share of YingShi Innovation in panoramic cameras is the highest, with over 70% of its revenue coming from overseas markets and an average gross margin exceeding 50% [1][2] - The revenue and net profit of Baiwei Storage are projected to grow approximately threefold and fivefold, respectively, from 2020 to 2024 [2] - Shenzhen's listed companies are expected to have a combined R&D expenditure of 196.7 billion yuan in 2024, reflecting a year-on-year increase of 10.8% [2] Group 3 - Shenzhen's Saltian Port handles over one-third of Guangdong's foreign trade import and export volume, with a trade value exceeding 1 trillion yuan in the first seven months of the year [3] - The city is recognized as the "first city of China's new energy vehicles," with BYD achieving a milestone of producing its 13 millionth vehicle [3][4] - Shenzhen has over 2,700 companies in the new energy vehicle industry, supported by a complete industrial chain [3] Group 4 - Shenzhen aims to become the "first city of the global low-altitude economy," with significant advancements in eVTOL technology and logistics [4] - The city has established nearly 300 drone routes, completing over 1.7 million cargo flights, marking a significant achievement in commercial applications [4][5] - The number of companies in Shenzhen's robotics industry is projected to reach 74,032 by 2024, with 34 listed companies and 9 unicorns [5] Group 5 - The financial sector in Shenzhen is projected to achieve a value-added of 471.05 billion yuan in 2024, growing by 4.2% [6] - Shenzhen's banking sector had total assets of 13.57 trillion yuan by the end of 2024, while the insurance sector's total assets reached 7.3 trillion yuan [6] - In 2024, 11 companies in Shenzhen successfully listed on the A-share market, raising 9.392 billion yuan, leading the nation in both the number of listings and fundraising [7] Group 6 - Shenzhen's GDP is expected to reach 3.68 trillion yuan in 2024, with a year-on-year growth of 5.8% [8] - The city's GDP for the first half of 2025 is projected to be 1.83 trillion yuan, reflecting a growth of 5.1% [8] - The ongoing development of innovative and capital-driven strategies is essential for Shenzhen to navigate global challenges and maintain its economic momentum [8]